ABSTRACT
In whole cells, (Fig. 1B) . In contrast, in cells with the mutant receptor ARL, cyproterone acetate and hydroxyflutamide induced LUC activity to the same level as that observed with R1881, dihydrotestosterone, and testosterone (Fig. 1C ). Some partial agonistic activity of RU 23908 on ARL was found, whereas RU 38486 and ICI 176.334 did not activate ARL. The lack of agonistic activity of RU 38486 and ICI 176.334 was not due to the absence of binding to the mutant ARL, as LUC activity induced by 0.1 nM R1881 could be inhibited with both antihormones ( Fig. 1D ). CHO cells contain a limited amount of glucocorticoid receptors, and RU 38486 is able to bind to these receptors.
However, the effect of RU 38486 on transcription activation was not due to this receptor system; in the absence of AR or ARL expression vectors, RU 38486 failed to induce LUC activity from the transfected MMTV-LUC reporter plasmid (not shown). Fig. 2A) . The down-regulation of promoter activity was dependent on the number of inserts; it was the largest with the CMV-(ARE),-LUC plasmid (remaining activity compared to control, 47%). In the absence of hormone, no differences in LUC activity between the different reporter plasmids were observed.
Overexpression of a transcription factor could sequester other factors necessary for the transcriptional activity of a promoter (i.e. squelching) (33). As squelching does not require specific DNA binding or an intact DNA-binding domain, the receptor mutant AR64 was studied to further verify that the reduction in promoter activity was actually due to DNA binding of the AR to the CMV-(ARE),-LUC plasmid. In this receptor mutant, the structure of the first zinc cluster is disrupted by the replacement of two of the four cysteine residues. Mutagenesis experiments have shown that these cysteine residues are essential for DNA-binding capacity of the receptor (34). No effect on LUC expression was seen, when CMV-(ARE),-LUC plasmid was cotransfected with the AR64 expression plasmid in CHO cells in the presence of ligand (Fig. 2B) ference were reached at 1 nM R1881 and set at 100% activation or inhibition, respectively. The dose-response curve of R1881 on transcription activation matched the effect of R1881 on promoter interference (Fig. 3) . Because promoter interference in this assay system reflects DNA binding of the AR, these results also indicate a direct correlation between the percent DNA binding and transcription activation.
Influence of different hormones and antihormones on DNAbinding ability of AR
The promoter interference assay permits the study of DNA binding of the receptor in whole cells. Therefore, we examined the effects of several hormones and antihormones on their ability to reduce promoter activity of the CMV-(ARE),-LUC plasmid in the presence of either the wild-type AR or the mutant ARL. Neither receptor interacted with the promoter interference construct in the absence of R1881, and treatment with R1881(1 nM) resulted in a similar decrease (to 50%) of LUC activity. This implies a similar dependence on the ligand R1881 for DNA binding of both the AR and ARL to the ARES in the promoter interference construct. CHO cells exposed to the natural androgens dihydrotestosterone (1 nM) and testosterone (10 nM) displayed a comparable reduction in the promoter activity of the CMV-(ARE),-LUC plasmid, as found with 1 nM R1881 (defined as 100% inhibition; Fig. 4,  A and B) . Cells expressing the wild-type AR and incubated with the antagonists cyproterone acetate (100 nM) and RU 38486 (100 nM) also showed promoter interference, although less than that in the presence of androgens (Fig. 4A) . The complete antagonists hydroxyflutamide (1 PM), ICI 176.334 (1 PM), and RU 23908 (1 FM) only slightly affected the promoter activity of the reporter plasmid (Fig. 4A) (29) and phosphorylation status of the receptor (37), we wanted to exclude the possibility that the differences in the promoter interference assay were due to differences in receptor expression levels. Therefore, extracts were prepared from transfected cells after treatment with the various ligands, and receptors were analyzed by Western blotting.
In the absence of hormone, the wild-type receptor and the mutant receptor AR64 migrated as two protein bands (110-112 kDa; Fig. 2C ). The difference in electrophoretic mobility represents differences in the degree of phosphorylation of the receptor (35-37). An additional decrease in the electrophoretic mobility of the receptor protein was ob- served, when CHO cells, expressing the wild-type AR, were incubated in the presence of R1881 (Fig. 2C) . These results are in agreement with observations described by others (37) and suggest the appearance of an additional protein form in the presence of R1881. The additional decrease in electrophoretic mobility was not observed for the mutant receptor AR64 in the presence of R1881 (Fig. 2C) (37) . The expression levels of wild-type receptor (Fig. 5A ) and mutant ARL (Fig. 5B ) also increased in the presence of the natural androgens dihydrotestosterone and testosterone. In contrast, binding of antagonists to both receptors, even those antagonists that showed agonist activity with ARL, did not affect receptor expression levels (Fig. 5, A and B) . This indicates that for all antiandrogens studied, the receptor expression levels were comparable, and variations in promoter interference between the various antiandrogen-bound receptors could not be explained by differences in receptor expression levels.
Discussion
An essential step in androgen action is transformation of the AR from a complex with heat shock proteins (27) 
